The fintech company October has launched instant lending for SMEs which, thanks to the predictive analysis of credit risk, allows a fully automatic evaluation of loan applications of between $34,000 and $284,000 (€30,000 and €250,000) and covered by the state guarantee.
October’s instant lending uses machine learning techniques to assess the risk of company default and is based on the previous analysis of the more than 131 thousand loan applications received by the platform from 2015 to date in the various countries where it is active.
Read more about the instant lending solution offered by the fintech company October and be the first to find the most important finance news in the world with our companion app, Born2Invest.
The instant lending solution is already operational in France and Italy
The tests carried out by the digital lending platform show how the algorithm provides extremely accurate results, allowing October to accurately predict a company’s risk of default, thus reducing the time needed to approve the financing to a few minutes. The instant lending solution is already operational in France and Italy and further reduces the already short time required for the fintech standard financing process, which provides 7 days for the disbursement of funds to the company’s account from the submission of the application.
Sergio Zocchi, CEO of October Italia, commented: “We have put the work done in the last 5 years to make our financing process even faster and more effective. In the current context, thanks to the new instant lending solution and the government guarantees that protect our lenders, eligible SMEs can access credit immediately. For the economic recovery, it is essential that entrepreneurs are able to finance themselves quickly by focusing time and energy on their core business.”
October, founded by Oliver Goy in 2014 under the name of Lendix, received in June 2018 a round of financing of $36.4 million (€32 million) from venture capital funds and other investors (including Carlo De Benedetti’s CIR). At the end of October 2018, the company changed its name to October. With over $483.8 million (€425 million) in loans disbursed and distributed over a total of 885 projects (figures at the end of June 2020), October is the lending platform for the leading SMEs in continental Europe.
Operating in Italy since May 2017, October has financed 156 business projects for more than $86.5 million (€76 million) at the end of June 2020. In October 2019, the platform announced the first $34 million (€30 million) closing of the new October Italia direct lending fund, dedicated to investments in loans to Italian SMEs offered on the same October platform. The new fund has the support of five Confidi members of Federconfidi and Rete Fidi Italia and the European Investment Fund, through the InnovFin guarantee instrument. The first closing of the fund has been signed by Neafidi, Confidi Systema!, Fidimpresa Italia, Confidi Sardegna and Confidi Centro and new investors are expected to join in the coming months. The fund has been operational since last April.
In July 2019, October launched October SME IV, an Eltif (European Long Term Investment Fund), worth $284.7 – $341 million (€250 – €300 million), dedicated to European SMEs, including Italy. In January 2018, the closing of the $227.7 million (€200 million) Lendix SME Loans fund III was announced, which was underwritten by Zencap Asset Management, Matmut Frères Investissements, Groupama, Fei, Eiffel IM, Decaux Frères Investissements and CNP Assurances.
The first Eltif was launched in 2016 under the name Lendix SME Loans fund II. Last June, Frigiolini & Partners Merchant and the subsidiary equity crowdfunding platform Fundera signed an agreement with the Italian branch of October to collaborate on alternative finance projects dedicated to SMEs, in particular minibonds and direct lending.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Be Beez, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
How to create an Email marketing campaign your audience will love
Whether you sell a product or service, work from a home office or a corporate one, starting an email campaign...
Top 10 Forex Risks To Consider Before Starting Currency Trade
This article shows you the fx risk to expect while performing forex trade and how to mitigate them and ensure...
Why are investments in the fintech sector set to break records this year
The fintech sector has had a great year so far, according to investor Humberto Herrera Rincón Gallardo, who thinks that...
Biotech companies are getting closer to find the eagerly awaited COVID-19 vaccine
Moderna agreed to sell its coronavirus drug at a "pandemic price" of $32-37 per dose.The biotech company registered losses of...
Switzerland returns $35.6 million to cannabis light producers
Swiss companies producing light cannabis products have received $35.6 million (€30 million) from the customs authorities for illegal taxes previously...
Biotech6 days ago
The Spanish pharma sector increased its profit by 18.4% in the first semester of the year
Business6 days ago
The financial guide for newlywed millennials
Featured5 days ago
The Italian fintech company Fido closes a €1.1 million financing round
Business5 days ago
PR Tech: How investments in the media market changed?